Skip to main content
. 2018 Jan 8;75(3):312–319. doi: 10.1001/jamaneurol.2017.4019

Figure 1. Longitudinal Trajectories of Mean Unified Parkinson’s Disease Rating Scale III (UPDRS III) Scores for Patients With Parkinson Disease (PD) Who Carry the Leucine-Rich Repeat Kinase 2 (LRRK2) Mutation Compared With Patients With Idiopathic PD (IPD).

Figure 1.

Longitudinal trajectories of mean UPDRS III scores show slower progression for patients with PD who carry the LRRK2 mutation than for patients with IPD. This included individuals sampled at different time points in the course of the disease. Individuals were followed up between 0 and 6 follow-up visits. Thus, no individual was followed up for the full duration described on the x-axis. The graphs demonstrate the mean UDPRS III score change in the IPD and LRRK2 PD groups with covariates fixed at the following values: baseline age = 67 years, baseline disease duration = 0 years, Montreal Cognitive Assessment score = 25, levodopa-equivalent dose = 457 mg levodopa, sex = female, and site = Tel Aviv. Trajectories are adjusted for the covariates described in Table 2. Spaghetti plots demonstrating the change for individual participants are shown in eFigure 5 in the Supplement.